Topics:

Eisai Acquires Four Oncology- Related Products From Ligand

Eisai Acquires Four Oncology- Related Products From Ligand

TEANECK, New Jersey—Eisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.

 
Loading comments...
Please Wait 20 seconds or click here to close